Grafa News and Videos — Page 121

Santacruz Silver Mining (NASDAQ:SCZM) acquired a 500-tonne-per-day milling facility in Bolivia to process ore from its wholly owned subsidiary San Lucas and support expansion of its third-party ore-sourcing business.

MISTRAS Group (NYSE:MG) agreed to be acquired by affiliates of H.I.G. Capital for $20.35 per share in cash, representing an enterprise value of approximately $866 million including outstanding debt.

BlossomHill Therapeutics (NASDAQ:BLSM) reported second quarter 2026 financial results and pipeline progress, highlighting its strengthened cash position following an upsized initial public offering.

The Cato Corporation (NYSE:CATO) plans to close approximately 70 additional underperforming stores during the third and fourth quarters of fiscal 2026, bringing total planned store closures for the year to about 120 locations.

Merck (NYSE:MRK) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending KEYTRUDA (pembrolizumab) combined with Padcev (enfortumab vedotin-ejfv) for adults with resectable muscle-invasive bladder cancer.

Xenon Pharmaceuticals (NASDAQ:XENE) shares declined after the company temporarily paused new patient enrollment in clinical studies evaluating its drug candidate for major depression and bipolar depression.

Novo Nordisk (NYSE:NVO) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending once-weekly Sogroya (somapacitan) for children in Europe with idiopathic short stature and persistent growth disturbance.

U.S.-listed gold mining shares gained before the market opened as rising bullion prices lifted the sector, with spot gold reaching $4,377.32 per ounce.

The Ensign Group (NASDAQ:ENSG) declared a quarterly cash dividend of $0.0650 per share of common stock, payable on or before October 31, 2026.

Natera (NASDAQ:NTRA) presented new data from its Signatera molecular residual disease (MRD) test at the IASLC 2026 World Conference on Lung Cancer, including results from a 1,129-patient analysis in early-stage non-small cell lung cancer.